Polyamine Scaffold Inhibitors for Drug-Resistant Tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against multi-drug resistant tuberculosis (MDR-TB) and extensively-drug resistant tuberculosis (XDR-TB) due to increasing microbial resistance, necessitating the development of novel antibacterial compounds targeting new mechanisms to avoid cross-resistance.
Innovation Solution
Development of polyamine scaffold-based compounds that inhibit bacterial topoisomerase I, specifically targeting Mycobacterium tuberculosis and other drug-resistant pathogens, including those in biofilms, with selective inhibition over DNA gyrase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibiotics are used to treat bacterial infections, then treatment is effective against susceptible bacteria, but treatment fails against multi-drug resistant tuberculosis (MDR-TB) and extensively-drug resistant tuberculosis (XDR-TB)
Solution Approach 1:
The patent segments the antibacterial therapy approach by introducing a completely new target class (topoisomerase I) separate from existing targets (DNA gyrase, topoisomerase IV). This segmentation creates independent treatment pathways that bypass resistance mechanisms developed against current antibiotics, allowing effective treatment of MDR-TB and XDR-TB cases that have failed conventional therapies.
Solution Approach 2:
The patent changes the fundamental parameter of the target enzyme from type IIA topoisomerases (DNA gyrase, topoisomerase IV) to type IA topoisomerase I. This parameter change represents a shift in molecular target class, enabling the development of novel antibiotics that act through a different mechanism and are not subject to cross-resistance with existing antibacterial agents.
2Adaptability or versatility
If novel antibacterial compounds are developed against new targets, then cross-resistance is avoided, but development complexity and time increase
Solution Approach 1:
The patent identifies topoisomerase I as a universal target present in all bacterial pathogens, including both M. tuberculosis and other bacteria. This universality allows a single compound class to address multiple resistance problems across different pathogens, reducing overall development complexity by creating a broadly applicable solution rather than pathogen-specific treatments.
Solution Approach 2:
The patent leverages the essential nature of topoisomerase I for bacterial viability - the enzyme performs critical DNA topology regulation functions that bacteria cannot perform without it. This self-service principle means that inhibiting this enzyme automatically leads to bacterial cell death, simplifying the drug development process by relying on the pathogen's own essential biology rather than requiring complex external mechanisms.
3Productivity
If topoisomerase I is inhibited by small molecules, then bacterial growth is halted, but selectivity over host topoisomerase must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that match the unique active site architecture of bacterial topoisomerase I. The chemical structures are optimized to interact with bacterial-specific amino acid residues and cofactors (such as NAD+) in the topoisomerase I active site, creating localized molecular recognition that distinguishes bacterial from host enzymes and ensures selective inhibition.
Solution Approach 2:
The patent uses NAD+ binding as an intermediary mechanism for selective inhibition. Bacterial topoisomerase I requires NAD+ as a cofactor for its enzymatic activity, and the patent compounds are designed to interact with the NAD+ binding site. This intermediary NAD+ interaction serves as a selectivity filter, as host topoisomerase I has different cofactor requirements and binding characteristics, thereby protecting human cells from inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate bactericidal activity against M. tuberculosis and other drug-resistant bacteria, effectively inhibiting topoisomerase I, thereby offering a potential treatment for MDR-TB and XDR-TB.
Implementation Method 1
These compounds and methods according to the current invention can further be used against bacterial pathogens. In one embodiment, the compound comprises a polyamine scaffold. The scaffold comprises one or more amine groups in the core structure.
Data Source
AI summary
The present invention provides novel compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases.